Bevacizumab 2.5 mg/0.1 mL
Recall D-0531-2023, part of FDA recall event 91972. See Pine Pharmaceuticals's company page.
Pine Pharmaceuticals, LLC started this Class III drug recall on Mar 27, 2023 (voluntary: firm initiated); FDA lists it as terminated, terminated Jun 1, 2023.
- Classification: Class III
- Started: Mar 27, 2023
- Status: Terminated
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
- Product
- Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1
- Quantity
- 932 syringes
- Lots and codes
- Lot # 66377, Exp. Date: 06/28/2023. Syringe may be labeled incorrectly as lot# 66316
- Distribution
- Nationwide in the USA
- Recalling firm
- Pine Pharmaceuticals, LLC, Tonawanda, NY, United States
- How the firm notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- FDA classified
- Apr 13, 2023
Newest first, one product per recall event; search them all
- Tropi-Phen (tropicamide 1%, phenylephrine 2.5%) ophthalmic solution, 5mL multi-use dropper, Rx only, Compounded by Pine…D-0063-2024 · Class II · Oct 2, 2023 · Terminated
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports